Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KINETA, INC./DEPTI · Entity 77778 | Chief Financial Officer | March 01, 2018 | March 05, 2018 |
| Rallybio CorpRLYB · Entity 6838 | Director | July 06, 2026 | July 10, 2026 |
| Shattuck Labs, Inc.STTK · Entity 5224 | Director | May 29, 2026 | June 03, 2026 |
| Tvardi Therapeutics, Inc.CARA · Entity 7579 | Director | June 04, 2024 | June 06, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KINETA, INC./DE
Report date March 01, 2018 · Filed March 05, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.11 · Expires 2028-03-01 | Direct | 78,000 |
Reported balance
After 2018-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-03-01 · Grant · Acquired 78,000 · Balance 78,000 F1: These securities shall vest and become exercisable in a series of installments, with the first installment to become exercisable for 25% of the underlying common stock on February 1, 2019, and thereafter vesting and becoming exercisable in 12 quarterly installments as nearly equal as practicable (as determined by the Issuer in its reasonable discretion), until such stock option becomes fully exercisable on February 1, 2022, provided that the Reporting Person remains an employee of Issuer at all times during the applicable vesting period of such securities. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities shall vest and become exercisable in a series of installments, with the first installment to become exercisable for 25% of the underlying common stock on February 1, 2019, and thereafter vesting and becoming exercisable in 12 quarterly installments as nearly equal as practicable (as determined by the Issuer in its reasonable discretion), until such stock option becomes fully exercisable on February 1, 2022, provided that the Reporting Person remains an employee of Issuer at all times during the applicable vesting period of such securities.
Rallybio Corp
Report date July 06, 2026 · Filed July 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,542 |
Reported balance
After 2026-07-06 transaction · row 1
1 source rowRow 1 · 2026-07-06 · Exercise / conversion · Acquired 3,562 · Balance 6,542 |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.38 · Expires 2035-05-13 | Direct | 0 |
Reported balance
After 2026-07-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-06 · Exercise / conversion · Disposed 3,562 · Balance 0 |
Shattuck Labs, Inc.
Report date May 29, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.95 · Expires 2036-05-29 | Direct | 81,000 |
Reported balance
After 2026-05-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-29 · Grant · Acquired 81,000 · Balance 81,000 F1: This option represents the right to purchase a total of 81,000 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents the right to purchase a total of 81,000 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer.
Tvardi Therapeutics, Inc.
Report date June 04, 2024 · Filed June 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 150,647 |
Reported balance
After 2024-06-04 transaction · row 1
1 source rowRow 1 · 2024-06-04 · Grant · Acquired 150,647 · Balance 150,647 F1: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.66 · Expires 2034-06-04 | Direct | 195,000 |
Reported balance
After 2024-06-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-04 · Grant · Acquired 195,000 · Balance 195,000 F2: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.
F2: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Premier, Inc.
Report date November 25, 2025 · Filed November 26, 2025
Section 16 reporting ended · disclosed 2025-11-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-11-25 transaction · row 1
1 source rowRow 1 · 2025-11-25 · Disposition to issuer · Disposed 18,668 · Balance 0 F1: Reflects the disposition of shares of Class A Common Stock, par value $0.01 per share ("Common Stock") of Premier, Inc. ("Issuer") pursuant to the consummation of the transactions contemplated by the Agreement and Plan of Merger dated as of September 21, 2025 (the "Merger Agreement") by and among the Issuer, Premium Parent, LLC ("Parent") and Premium Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, at the effective time of the Merger on November 25, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the Effective Time, each issued and outstanding share of Common Stock was cancelled and converted automatically into the right to receive $28.25 in cash, without interest (the "Merger Consideration"), subject to certain exceptions set forth in the Merger Agreement. F2: The shares of the Issuer's Common Stock reported as disposed of by the reporting person include shares of Common Stock underlying outstanding time-based vesting restricted stock unit awards previously reported as beneficially owned by the reporting person ("RSUs") and granted to the reporting person prior to August 16, 2025. Pursuant to the Merger Agreement, at the Effective Time, each of these RSUs was cancelled and converted into the right to receive an amount in cash, without interest, equal to the number of shares of Common Stock subject to the RSUs multiplied by the Merger Consideration (together with any accrued cash dividend equivalents). |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of Class A Common Stock, par value $0.01 per share ("Common Stock") of Premier, Inc. ("Issuer") pursuant to the consummation of the transactions contemplated by the Agreement and Plan of Merger dated as of September 21, 2025 (the "Merger Agreement") by and among the Issuer, Premium Parent, LLC ("Parent") and Premium Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, at the effective time of the Merger on November 25, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the Effective Time, each issued and outstanding share of Common Stock was cancelled and converted automatically into the right to receive $28.25 in cash, without interest (the "Merger Consideration"), subject to certain exceptions set forth in the Merger Agreement.
F2: The shares of the Issuer's Common Stock reported as disposed of by the reporting person include shares of Common Stock underlying outstanding time-based vesting restricted stock unit awards previously reported as beneficially owned by the reporting person ("RSUs") and granted to the reporting person prior to August 16, 2025. Pursuant to the Merger Agreement, at the Effective Time, each of these RSUs was cancelled and converted into the right to receive an amount in cash, without interest, equal to the number of shares of Common Stock subject to the RSUs multiplied by the Merger Consideration (together with any accrued cash dividend equivalents).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 06, 2026 Filed Jul 10, 2026 20:14 UTC | Rallybio Corp RLYB · Entity 6838 | Exercise / conversionOption (Right to Buy) · Derivative | 3,562 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0001193125-26-300913 · ownership.xml · derivative · entry 2 Boudreau Helen M · CIK 0001661481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,562 shares Expires 2035-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2026 Filed Jul 10, 2026 20:14 UTC | Rallybio Corp RLYB · Entity 6838 | Exercise / conversionCommon Stock | 3,562 | $2.38 | $8,477.56 |
DisclosureSEC source: 0001193125-26-300913 · ownership.xml · nonDerivative · entry 1 Boudreau Helen M · CIK 0001661481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 29, 2026 Filed Jun 3, 2026 00:00 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 81,000 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001193125-26-254122 · ownership.xml · derivative · entry 1 Boudreau Helen M · CIK 0001661481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,000 Underlying: Common Stock · 81,000 shares Expires 2036-05-29 F1 · derivative.exercise_date: This option represents the right to purchase a total of 81,000 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 15:13 UTC | Premier, Inc. PINC · Entity 72504 | Disposition to issuerClass A Common Stock | 18,668 | $28.25 | $527,371.00 |
DisclosureSEC source: 0001193125-25-298830 · ownership.xml · nonDerivative · entry 1 Boudreau Helen M · CIK 0001661481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Reflects the disposition of shares of Class A Common Stock, par value $0.01 per share ("Common Stock") of Premier, Inc. ("Issuer") pursuant to the consummation of the transactions contemplated by the Agreement and Plan of Merger dated as of September 21, 2025 (the "Merger Agreement") by and among the Issuer, Premium Parent, LLC ("Parent") and Premium Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, at the effective time of the Merger on November 25, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the Effective Time, each issued and outstanding share of Common Stock was cancelled and converted automatically into the right to receive $28.25 in cash, without interest (the "Merger Consideration"), subject to certain exceptions set forth in the Merger Agreement. F2 · kind: The shares of the Issuer's Common Stock reported as disposed of by the reporting person include shares of Common Stock underlying outstanding time-based vesting restricted stock unit awards previously reported as beneficially owned by the reporting person ("RSUs") and granted to the reporting person prior to August 16, 2025. Pursuant to the Merger Agreement, at the Effective Time, each of these RSUs was cancelled and converted into the right to receive an amount in cash, without interest, equal to the number of shares of Common Stock subject to the RSUs multiplied by the Merger Consideration (together with any accrued cash dividend equivalents). F1 · price: Reflects the disposition of shares of Class A Common Stock, par value $0.01 per share ("Common Stock") of Premier, Inc. ("Issuer") pursuant to the consummation of the transactions contemplated by the Agreement and Plan of Merger dated as of September 21, 2025 (the "Merger Agreement") by and among the Issuer, Premium Parent, LLC ("Parent") and Premium Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, at the effective time of the Merger on November 25, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the Effective Time, each issued and outstanding share of Common Stock was cancelled and converted automatically into the right to receive $28.25 in cash, without interest (the "Merger Consideration"), subject to certain exceptions set forth in the Merger Agreement. F2 · price: The shares of the Issuer's Common Stock reported as disposed of by the reporting person include shares of Common Stock underlying outstanding time-based vesting restricted stock unit awards previously reported as beneficially owned by the reporting person ("RSUs") and granted to the reporting person prior to August 16, 2025. Pursuant to the Merger Agreement, at the Effective Time, each of these RSUs was cancelled and converted into the right to receive an amount in cash, without interest, equal to the number of shares of Common Stock subject to the RSUs multiplied by the Merger Consideration (together with any accrued cash dividend equivalents). Read SEC document |
| July 14, 2025 Filed Jul 16, 2025 20:05 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 33,150 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0000950170-25-096242 · ownership.xml · derivative · entry 1 Boudreau Helen M · CIK 0001661481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,150 Underlying: Common Stock · 33,150 shares Expires 2035-07-14 F1 · derivative.exercise_date: This option represents the right to purchase a total of 33,150 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 30, 2025 Filed Jun 2, 2025 21:43 UTC | Premier, Inc. PINC · Entity 72504 | SaleClass A Common Stock | 2,000 | $22.88 | $45,760.00 |
DisclosureSEC source: 0000950170-25-080414 · ownership.xml · nonDerivative · entry 1 Boudreau Helen M · CIK 0001661481 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,668 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 20, 2025. Read SEC document |
| May 13, 2025 Filed May 15, 2025 21:10 UTC | Rallybio Corp RLYB · Entity 6838 | GrantOption (Right to Buy) · Derivative | 28,500 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001739410-25-000087 · wk-form4_1747343402.xml · derivative · entry 1 Boudreau Helen M · CIK 0001661481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,500 Underlying: Common Stock · 28,500 shares Expires 2035-05-13 F1 · derivative.exercise_date: The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 13, 2026 or the date of the Company's 2026 Annual Meeting of Stockholders. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 19:38 UTC | Premier, Inc. PINC · Entity 72504 | SaleClass A Common Stock | 2,500 | $21.42 | $53,550.00 |
DisclosureSEC source: 0000950170-25-002730 · ownership.xml · nonDerivative · entry 1 Boudreau Helen M · CIK 0001661481 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,668 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 8, 2024. F2 · price: The reported price in Column 4 is the weighted average price of all shares sold on the reported date in multiple transactions at prices ranging from $21.17 to $21.70. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 20:21 UTC | Premier, Inc. PINC · Entity 72504 | GrantClass A Common Stock | 7,101 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-134910 · ownership.xml · nonDerivative · entry 1 Boudreau Helen M · CIK 0001661481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,168 Read SEC document |
| June 21, 2024 Filed Jun 21, 2024 22:04 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 27,700 | $0.00 Strike: $4.37 | $0.00 |
DisclosureSEC source: 0000950170-24-076384 · ownership.xml · derivative · entry 1 Boudreau Helen M · CIK 0001661481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,700 Underlying: Common Stock · 27,700 shares Expires 2034-06-21 F1 · derivative.exercise_date: This option represents the right to purchase a total of 27,700 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:28 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 195,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001415889-24-015765 · form4-06062024_080604.xml · derivative · entry 2 Boudreau Helen M · CIK 0001661481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Stock · 195,000 shares Expires 2034-06-04 F2 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:28 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 150,647 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015765 · form4-06062024_080604.xml · nonDerivative · entry 1 Boudreau Helen M · CIK 0001661481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,647 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| May 15, 2024 Filed May 16, 2024 19:12 UTC | Premier, Inc. PINC · Entity 72504 | SaleClass A Common Stock | 6,629 | $19.85 | $131,585.65 |
DisclosureSEC source: 0000950170-24-061022 · ownership.xml · nonDerivative · entry 1 Boudreau Helen M · CIK 0001661481 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,067 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 8, 2024. F2 · price: The reported price in Column 4 is the weighted average price of all shares sold on the reported date in multiple transactions at prices ranging from $19.73 to $19.91. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 15, 2024 Filed May 17, 2024 21:05 UTC | Rallybio Corp RLYB · Entity 6838 | GrantOption (Right to Buy) · Derivative | 16,500 | $0.00 Strike: $1.91 | $0.00 |
DisclosureSEC source: 0001739410-24-000093 · wk-form4_1715979949.xml · derivative · entry 1 Boudreau Helen M · CIK 0001661481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2034-05-15 F1 · derivative.exercise_date: The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 15, 2025 or the date of the Company's 2025 Annual Meeting of Stockholders. Read SEC document |
| December 04, 2023 Filed Dec 5, 2023 22:11 UTC | Premier, Inc. PINC · Entity 72504 | GrantClass A Common Stock | 7,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-057475 · doc4.xml · nonDerivative · entry 1 Boudreau Helen M · CIK 0001661481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,696 Read SEC document |
| August 02, 2023 Filed Aug 4, 2023 21:20 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 155,747 | $0.00 Strike: $3.09 | $0.00 |
DisclosureSEC source: 0001209191-23-044635 · doc4.xml · derivative · entry 1 Boudreau Helen M · CIK 0001661481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,747 Underlying: Common Stock · 155,747 shares Expires 2033-08-02 F1 · derivative.exercise_date: This option shall vest and become exercisable in twelve (12) equal quarterly installments beginning on August 2, 2023 such that the option will be fully vested and exercisable on August 2, 2026, subject to the Reporting Person's continued service to the Issuer on each such date. Read SEC document |
| May 26, 2023 Filed May 31, 2023 20:43 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 40,258 | $0.00 Strike: $2.72 | $0.00 |
DisclosureSEC source: 0000950170-23-025380 · ownership.xml · derivative · entry 1 Boudreau Helen M · CIK 0001661481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,258 Underlying: Common Stock · 40,258 shares Expires 2033-05-26 F1 · derivative.exercise_date: This option represents the right to purchase a total of 40,258 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 17, 2023 Filed May 19, 2023 21:25 UTC | Rallybio Corp RLYB · Entity 6838 | GrantOption (Right to Buy) · Derivative | 15,490 | $0.00 Strike: $5.64 | $0.00 |
DisclosureSEC source: 0000899243-23-013405 · doc4.xml · derivative · entry 1 Boudreau Helen M · CIK 0001661481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,490 Underlying: Common Stock · 15,490 shares Expires 2033-05-17 F1 · derivative.exercise_date: The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 17, 2024 or the date of the Company's 2024 Annual Meeting of Stockholders. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 22:08 UTC | Premier, Inc. PINC · Entity 72504 | GrantClass A Common Stock | 4,636 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-060180 · doc4.xml · nonDerivative · entry 1 Boudreau Helen M · CIK 0001661481 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,363 Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:31 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 40,258 | $0.00 Strike: $4.32 | $0.00 |
DisclosureSEC source: 0000899243-22-021923 · doc4.xml · derivative · entry 1 Boudreau Helen M · CIK 0001661481 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,258 Underlying: Common Stock · 40,258 shares Expires 2032-06-08 F1 · derivative.exercise_date: This option represents a right to purchase a total of 40,258 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 24, 2022 Filed May 27, 2022 00:09 UTC | Rallybio Corp RLYB · Entity 6838 | GrantOption (Right to Buy) · Derivative | 13,440 | $0.00 Strike: $12.75 | $0.00 |
DisclosureSEC source: 0000899243-22-019830 · doc4.xml · derivative · entry 1 Boudreau Helen M · CIK 0001661481 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,440 Underlying: Common Stock · 13,440 shares Expires 2032-05-24 F1 · derivative.exercise_date: The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 24, 2023 or the date of the Company's 2023 Annual Meeting of Stockholders. Read SEC document |
| December 06, 2021 Filed Dec 7, 2021 13:29 UTC | Premier, Inc. PINC · Entity 72504 | GrantClass A Common Stock | 4,098 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-068239 · doc4.xml · nonDerivative · entry 1 Boudreau Helen M · CIK 0001661481 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,727 Read SEC document |
| June 19, 2021 Filed Jun 23, 2021 00:07 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 3,434 | $0.00 Strike: $29.34 | $0.00 |
DisclosureSEC source: 0000899243-21-025416 · doc4.xml · derivative · entry 1 Boudreau Helen M · CIK 0001661481 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,434 Underlying: Common Stock · 3,434 shares Expires 2031-06-19 F1 · derivative.exercise_date: This option represents a right to purchase a total of 3,434 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| December 22, 2020 Filed Dec 28, 2020 21:20 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 1,286 | $0.00 Strike: $53.02 | $0.00 |
DisclosureSEC source: 0000899243-20-035191 · doc4.xml · derivative · entry 1 Boudreau Helen M · CIK 0001661481 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,286 Underlying: Common Stock · 1,286 shares Expires 2030-12-22 F1 · derivative.exercise_date: This option represents a right to purchase a total of 1,286 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the next annual meeting of the Issuer's shareholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| December 07, 2020 Filed Dec 8, 2020 21:44 UTC | Premier, Inc. PINC · Entity 72504 | GrantClass A Common Stock | 6,629 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-062285 · doc4.xml · nonDerivative · entry 1 Boudreau Helen M · CIK 0001661481 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,629 Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 22:31 UTC | KINETA, INC./DE PTI · Entity 77778 | GrantEmployee Stock Option (Right to Buy) · Derivative | 78,000 | $0.00 Strike: $3.11 | $0.00 |
DisclosureSEC source: 0001209191-18-016683 · doc4.xml · derivative · entry 1 Boudreau Helen M · CIK 0001661481 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,000 Underlying: Common Stock · 78,000 shares Expires 2028-03-01 F1 · derivative.exercise_date: These securities shall vest and become exercisable in a series of installments, with the first installment to become exercisable for 25% of the underlying common stock on February 1, 2019, and thereafter vesting and becoming exercisable in 12 quarterly installments as nearly equal as practicable (as determined by the Issuer in its reasonable discretion), until such stock option becomes fully exercisable on February 1, 2022, provided that the Reporting Person remains an employee of Issuer at all times during the applicable vesting period of such securities. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 22:20 UTC | KINETA, INC./DE PTI · Entity 77778 | GrantRestricted Stock Units · Derivative | 13,759 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-007589 · doc4.xml · derivative · entry 1 Boudreau Helen M · CIK 0001661481 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,759 Underlying: Common Stock · 13,759 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of PTI common stock. F2 · derivative.exercise_date: The restricted stock units shall vest in full on February 1, 2019. F2 · derivative.expiration_date: The restricted stock units shall vest in full on February 1, 2019. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 20:39 UTC | KINETA, INC./DE PTI · Entity 77778 | GrantEmployee Stock Option (Right to Buy) · Derivative | 215,000 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0001209191-17-047371 · doc4.xml · derivative · entry 1 Boudreau Helen M · CIK 0001661481 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,000 Underlying: Common Stock · 215,000 shares Expires 2027-07-25 F1 · derivative.exercise_date: These securities shall vest and become exercisable in a series of installments, with the first installment to become exercisable for 25% of the underlying common stock on July 25, 2018, and thereafter vesting and becoming exercisable in quarterly installments as nearly equal as practicable (as determined by the Issuer in its reasonable discretion), until such stock option becomes fully exercisable on July 25, 2021, provided that the Reporting Person remains an employee of Issuer at all times during the applicable vesting period of such securities. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.